Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

BACKGROUND: LUX-Lung 3 showed afatinib improved progression-free survival (PFS) compared with cisplatin plus pemetrexed in patients with epidermal growth factor receptor (EGFR) mutations. In this study, chemotherapy efficacy tended to differ between patients with Leu858Arg (L858R) point mutation and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Kaneda, Toshihiko, Yoshioka, Hiroshige, Tamiya, Motohiro, Tamiya, Akihiro, Hata, Akito, Okada, Asukaka, Niwa, Takashi, Shiroyama, Takayuki, Kanazu, Masaki, Ishida, Tadashi, Katakami, Nobuyuki
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5749021/
https://ncbi.nlm.nih.gov/pubmed/29291705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3952-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki